RAPID JOINT IMPROVEMENT PROVEN TO LAST AT 2 YEARS*

ACR20 response at Week 24 after just 4 doses (primary endpoint) and an OLE active treatment NRI post hoc analysis from Weeks 24 to 1001-6

VIEW FULL DETAILS

EXTENSIVE RELIEF: MORE THAN JUST LASTING SKIN CLEARANCE AT 2 YEARS*

Improvement in IGA 0/1 at Weeks 24 and 100, with additional data including PASI 90, enthesitis, dactylitis, HAQ-DI, and MDA1-6

VIEW FULL DETAILS

PROVEN SAFETY PROFILE IN PSORIATIC DISEASE

Proven safety across 4 pivotal clinical trials in moderate to severe plaque psoriasis and active PsA1

VIEW FULL DETAILS

ROBUST COVERAGE
& DEDICATED PATIENT SUPPORT

Commercial coverage as strong as Humira® (adalimumab)—no step edit required7§||¶

VIEW FULL DETAILS